{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T09:07:13Z","timestamp":1791450433447,"version":"4.3.3"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T00:00:00Z","timestamp":1721260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The incidence of uveitis has risen with the use of targeted therapies, particularly prevalent in the administration of immune checkpoint inhibitors and MAP-kinase pathway inhibitors. We report the first case of VKH-like uveitis linked to Donafenib employed for the primary hepatocellular carcinoma, highlighting the necessity of ophthalmological follow-up in patients undergoing treatment with Donafenib.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>A 55-year-old man developed VKH-like symptoms, including sporadic white patches, tinnitus, headache, and mild bilateral vision reduction, after 18 months of treatment with Donafenib and Sintilimab for hepatocellular carcinoma. Based on ophthalmological examinations that fundus fluorescein angiography images demonstrating multiple focal areas of pinpoint hyperfluorescence, along with pooling indicative of neurosensory detachment and disc leakage in both eyes, choroid thickening in swept-source optical coherence tomography, and \u201csunset-glow\u201d fundus appearance, a tentative diagnosis of VKH-like uveitis was made. Initially, his best-corrected visual acuity (BCVA) was 20\/200 in the right eye and 20\/80 in the left eye. Upon discontinuing Donafenib and starting a 3-month course of oral glucocorticoids, his BCVA improved to 20\/30 in the right eye and 20\/40 in the left eye.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Targeted drugs have been commonly used for cancer treatment in recent years, but challenges of ocular side effects emerged gradually. To optimize patient outcomes, regular ophthalmological follow-ups are essential for those undergoing treatment with targeted therapies like Donafenib.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1401017","type":"journal-article","created":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T05:04:31Z","timestamp":1721279071000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["VKH-like uveitis during donafenib therapy for hepatocellular carcinoma: a case report and review of the literature"],"prefix":"10.3389","volume":"15","author":[{"given":"Rui","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guina","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.4103\/ijo.IJO_816_20","article-title":"Drug-induced uveitis: a review","volume":"68","author":"Agarwal","year":"2020","journal-title":"Indian J. Ophthalmol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1080\/09273948.2019.1597896","article-title":"Development of acute vogt-koyanagi-harada-like syndrome during the treatment course with vemurafenib for metastatic melanoma","volume":"28","author":"Apivatthakakul","year":"2020","journal-title":"Ocul. Immunol. Inflamm."},{"key":"B3","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1111\/1346-8138.13612","article-title":"Case of acute anterior uveitis and Vogt-Koyanagi-Harada syndrome-like eruptions induced by nivolumab in a melanoma patient","volume":"44","author":"Arai","year":"2017","journal-title":"J. Dermatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/S0140-6736(05)79382-X","article-title":"Arthritis, uveitis, and Stevens-Johnson syndrome induced by trimethoprim","volume":"351","author":"Arola","year":"1998","journal-title":"Lancet."},{"key":"B5","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/s0161-6420(00)00586-8","article-title":"Rifabutin-associated hypopyon uveitis in human immunodeficiency virus-negative immunocompetent individuals","volume":"108","author":"Bhagat","year":"2001","journal-title":"Ophthalmology."},{"key":"B6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1089\/jop.2022.0094","article-title":"Ocular side effects of bisphosphonates: a review of literature","volume":"39","author":"Chartrand","year":"2023","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"B20","unstructured":"Chinese expert consensus on clinical application of molecular targeted drugs in hepatocellular carcinoma (2022 edition)2655266810.3760\/cma.cn112137-20220623-01387Chin. Med. J.1022022"},{"key":"B7","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s00417-017-3835-2","article-title":"Checkpoint inhibitor-induced uveitis: a case series","volume":"256","author":"Conrady","year":"2018","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1080\/09273948.2020.1801286","article-title":"Immune checkpoint inhibitor-induced uveitis","volume":"28","author":"Cunningham","year":"2020","journal-title":"Ocul. Immunol. Inflamm."},{"key":"B9","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1001\/archopht.1997.01100150735008","article-title":"Iritis and hypotony after treatment with intravenous cidofovir for cytomegalovirus retinitis","volume":"115","author":"Davis","year":"1997","journal-title":"Arch. Ophthalmol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ejca.2020.11.027","article-title":"The association between immune checkpoint or BRAF\/MEK inhibitor therapy and uveitis in patients with advanced cutaneous melanoma","volume":"144","author":"Dimitriou","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.preteyeres.2016.02.002","article-title":"Vogt-Koyanagi-Harada disease: novel insights into pathophysiology, diagnosis and treatment","volume":"52","author":"Du","year":"2016","journal-title":"Prog. Retin Eye Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"E431","DOI":"10.1503\/cmaj.111752","article-title":"Inflammatory ocular adverse events with the use of oral bisphosphonates: a retrospective cohort study","volume":"184","author":"Etminan","year":"2012","journal-title":"Cmaj"},{"key":"B14","doi-asserted-by":"publisher","first-page":"390","DOI":"10.3109\/09273948.2013.808351","article-title":"Uveitis risk following oral fluoroquinolone therapy: a nested case-control Study","volume":"21","author":"Forooghian","year":"2013","journal-title":"Ocul. Immunol. Inflamm."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1136\/bjophthalmol-2020-316970","article-title":"Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo Clinic experience","volume":"105","author":"Fortes","year":"2021","journal-title":"Br. J. Ophthalmol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1089\/jop.2018.0019","article-title":"Oral anti-vascular endothelial growth factor drugs and ocular adverse events","volume":"34","author":"Fraunfelder","year":"2018","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.autrev.2013.01.004","article-title":"Vogt-Koyanagi-Harada syndrome","volume":"12","author":"Greco","year":"2013","journal-title":"Autoimmun. Rev."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e616","DOI":"10.1093\/oncolo\/oyae014","article-title":"Ocular effects of MEK inhibitor therapy: literature review, clinical presentation, and best practices for mitigation","volume":"29","author":"Jeng-Miller","year":"2024","journal-title":"Oncologist"},{"key":"B19","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13023-016-0412-4","article-title":"Vogt-Koyanagi-Harada disease: review of a rare autoimmune disease targeting antigens of melanocytes","volume":"11","author":"Lavezzo","year":"2016","journal-title":"Orphanet J. Rare Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s00280-020-04031-1","article-title":"A Phase I dose-escalation, pharmacokinetics and food-effect study of oral donafenib in patients with advanced solid tumours","volume":"85","author":"Li","year":"2020","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1080\/09273948.2016.1246666","article-title":"Uveitis and papillitis in the setting of dabrafenib and trametinib therapy for metastatic melanoma: a case report","volume":"26","author":"Lim","year":"2018","journal-title":"Ocul. Immunol. Inflamm."},{"key":"B23","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1111\/1759-7714.13327","article-title":"Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy","volume":"11","author":"Liu","year":"2020","journal-title":"Thorac. Cancer"},{"key":"B12","unstructured":"Expert consensus on the clinical application of donafenib in the treatment of hepatocellular carcinoma74975710.3969\/j.issn.1009-0460.2022.08.013J. Clin. Oncol.272022"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1016\/j.transproceed.2006.08.067","article-title":"Anterior uveitis associated with treatment with intravenous cidofovir in kidney transplant patients with BK virus nephropathy","volume":"38","author":"Lopez","year":"2006","journal-title":"Transpl. Proc."},{"key":"B25","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/s0039-6257(01)00261-2","article-title":"The tubulointerstitial nephritis and uveitis syndrome","volume":"46","author":"Mandeville","year":"2001","journal-title":"Surv. Ophthalmol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1097\/ICU.0000000000000530","article-title":"Drug-induced uveitis","volume":"29","author":"Moorthy","year":"2018","journal-title":"Curr. Opin. Ophthalmol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13023-017-0677-2","article-title":"Tubulointerstitial nephritis and uveitis (TINU) syndrome: a systematic review of its epidemiology, demographics and risk factors","volume":"12","author":"Okafor","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.survophthal.2016.05.002","article-title":"Vogt-Koyanagi-Harada disease","volume":"62","author":"O'Keefe","year":"2017","journal-title":"Surv. Ophthalmol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/sj.eye.6702483","article-title":"Bilateral acute anterior uveitis as a side effect of trimethoprim","volume":"21","author":"Pathak","year":"2007","journal-title":"Eye (Lond)."},{"key":"B30","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1200\/JCO.21.00163","article-title":"Donafenib versus sorafenib in first-line treatment of unresectable or metastatic hepatocellular carcinoma: a randomized, open-label, parallel-controlled phase II-III trial","volume":"39","author":"Qin","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.berh.2008.09.008","article-title":"Autoimmune diseases induced by TNF-targeted therapies","volume":"22","author":"Ramos-Casals","year":"2008","journal-title":"Best. Pract. Res. Clin. Rheumatol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1097\/CMR.0000000000000933","article-title":"Uveitis associated with immune checkpoint inhibitors or BRAF\/MEK inhibitors in patients with malignant melanoma","volume":"33","author":"Sada","year":"2023","journal-title":"Melanoma Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.autrev.2014.01.023","article-title":"Diagnosis and classification of Vogt-Koyanagi-Harada disease","volume":"13","author":"Sakata","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"B34","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1001\/jamaophthalmol.2015.4092","article-title":"Oral fluoroquinolones and the risk of uveitis","volume":"134","author":"Sandhu","year":"2016","journal-title":"JAMA Ophthalmol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3109\/09273948.2011.623213","article-title":"Sarcoid-related uveitis occurring during adalimumab therapy","volume":"20","author":"Seve","year":"2012","journal-title":"Ocul. Immunol. Inflamm."},{"key":"B36","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ophtha.2023.10.004","article-title":"Drug-induced uveitis related to checkpoint inhibitors and MAP-kinase inhibitors","volume":"131","author":"Thibault","year":"2024","journal-title":"Ophthalmology"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e391","DOI":"10.1016\/j.jfo.2017.11.035","article-title":"Rifabutin-associated uveitis in a 10-year-old child with HIV: case report and review of the literature","volume":"41","author":"Trone","year":"2018","journal-title":"J. Fr. Ophtalmol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"E03071","DOI":"10.3760\/cma.j.cmcr.2022.e03071","article-title":"Vemurafenib induced drug-uveitis and secondary glaucoma","author":"Xiaoli","year":"2022","journal-title":"Chin. Med. Care Repos."},{"key":"B39","doi-asserted-by":"publisher","first-page":"925","DOI":"10.3760\/cma.j.cn112142-20220215-00055","article-title":"Vogt-Koyanagi-Harada syndrome in the setting of vemurafenib therapy for metastatic melanoma: a case report","author":"Xiaotong","year":"2022","journal-title":"Chin. J. Ophthalmol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"452","DOI":"10.21037\/hbsn-20-480","article-title":"2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights","volume":"9","author":"Xie","year":"2020","journal-title":"Hepatobiliary Surg. Nutr."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1401017\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T05:04:37Z","timestamp":1721279077000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1401017\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,18]]},"references-count":40,"alternative-id":["10.3389\/fphar.2024.1401017"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1401017","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,18]]},"article-number":"1401017"}}